IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
September 28, 2020 08:45 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
August 04, 2020 16:10 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
July 15, 2020 08:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
April 23, 2020 07:30 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
April 07, 2020 16:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor providing...
Servier backs American startup’s research project at LabCentral
April 26, 2018 11:05 ET | LabCentral
Paris, France & Cambridge, US, April 26, 2018 (GLOBE NEWSWIRE) -- Independent international pharmaceutical company Servier and LabCentral, a well-known launchpad for innovative startups in the...